Praxis Precision Medicines (PRAX) EBIT (2019 - 2026)

Praxis Precision Medicines' EBIT history runs 8 years deep, the most recent figure standing at -$105.9 million for Q1 2026.

• On a quarterly basis, EBIT fell 41.66% year-over-year to -$105.9 million in Q1 2026; TTM through Mar 2026 was -$357.3 million, a 53.36% decrease from a year earlier, with the FY2025 full-year figure at -$326.2 million, down 62.96% from the prior year.
• EBIT fell to -$105.9 million in Q1 2026 per PRAX's latest filing, from -$97.0 million in the prior quarter.
• Across five years, EBIT topped out at -$25.5 million in Q3 2023 and bottomed at -$105.9 million in Q1 2026.
• The 5-year median for EBIT is -$56.8 million (2024), against an average of -$57.3 million.
• Across the five-year window, EBIT sank 151.1% in 2022 and surged 44.67% in 2023, its largest moves.
• Year by year, EBIT stood at -$41.5 million in 2022, then soared by 32.92% to -$27.8 million in 2023, then sank by 130.01% to -$64.0 million in 2024, then slumped by 51.74% to -$97.0 million in 2025, then fell by 9.08% to -$105.9 million in 2026.
• Per Business Quant, the three latest PRAX EBIT figures stand at -$105.9 million (Q1 2026), -$97.0 million (Q4 2025), and -$78.4 million (Q3 2025).